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Porcine reproductive and respiratory syndrome (PRRS) is a high-consequence animal disease with current vaccines providing
limited protection from infection due to the high degree of genetic variation of field PRRS virus. Therefore, understanding host
immune responses elicited by different PRRSV strains will facilitate the development of more effective vaccines. Using IngelVac
modified live PRRSV vaccine (MLV), its parental strain VR-2332, and the heterologous KS-06-72109 strain (a Kansas isolate of
PRRSV), we compared immune responses induced by vaccination and/or PRRSV infection. Our results showed that MLV can
provide complete protection from homologous virus (VR-2332) and partial protection from heterologous (KS-06) challenge. The
protection was associated with the levels of PRRSV neutralizing antibodies at the time of challenge, with vaccinated pigs having
higher titers to VR-2332 compared to KS-06 strain. Challenge strain did not alter the cytokine expression profiles in the serum
of vaccinated pigs or subpopulations of T cells. However, higher frequencies of IFN-𝛾-secreting PBMCs were generated from
pigs challenged with heterologous PRRSV in a recall response when PBMCs were re-stimulated with PRRSV. Thus, this study
indicates that serum neutralizing antibody titers are associated with PRRSV vaccination-induced protection against homologous
and heterologous challenge.
1. Introduction
Porcine reproductive and respiratory syndrome (PRRS) is an
economically important pandemic disease characterized by
reproductive failure in sows and respiratory disease in young
pigs. A recent study estimates that the total productivity losses
in the U.S. swine industry due to PRRS are currently $664
million annually, an increase from the $560 million annual
cost estimated in 2005 [1]. This indicates that not only does
PRRS have a significant financial impact on the pork industry
but also current strategies for reducing the burden of PRRS
virus are not adequate.
PRRS is caused by porcine reproductive and respira-
tory syndrome virus (PRRSV), which is a member of the
genusArterivirus, familyArteriviridae, and orderNidovirales.
PRRSV is known tomutate rapidly in both in vitro cell culture
models and in vivo in natural field infections [2]. The ability
of PRRSV to mutate rapidly creates genetically extensive
and antigenic diverse strains in both North American and
European field isolates [3]. The high genetic mutation rate
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of PRRSV poses a challenge for PRRSV vaccine develop-
ment [2]. Currently, both inactivated PRRSV vaccines and
modified live virus (MLV) PRRSV vaccines are widely used
to control the disease. However, inactivated vaccines as well
as modified live vaccines have been shown to be ineffective
in providing protective immunity to heterologous strains
of PRRSV at the herd level [4–7]. Therefore, development
of a broadly protective PRRSV vaccine will be one of the
most efficient solutions to control the prevalence of PRRS
worldwide.
It has been shown that pigs infected with PRRSV have
inadequate immune responses, such as delayed onset of
neutralizing antibody as well as weak interferon (IFN)-𝛾
responses [2, 8]. Development of different types of vaccines
aiming to increase host immune response and get broader
protection from various field PRRSV infections has been
proposed [9]. Currently, PRRSV-MLV is used to control the
disease worldwide. However, the high incidence of genetic
mutation during PRRSV transmission often results in vac-
cines based on strains of PPRSV isolated twenty years ago,
such as MLV, having limited protection from new emerging
viral strains. Disparity of immune responses elicited by dif-
ferent PRRSV strains was reported previously [10]. However,
the role of humoral and cellular immune responses was
not clearly elucidated in these reports with regard to the
protection from virus challengewith different PRRSV strains.
Therefore, dissecting the mechanisms of immune responses
that are predictive of protection against heterologous PRRSV
challenge will be valuable for the development of more effica-
cious vaccines. In this study, we investigated the differential
profiles of host immune responses in naive or vaccinated
pigs challenged with homologous and heterologous PRRSV
strains.
2. Materials and Methods
2.1. Cells and Virus. MARC-145 cells were maintained in
Modified Eagle’s medium (MEM) supplemented with 7%
fetal bovine serum (FBS) containing 100Upenicillin/mL and
100 𝜇g streptomycin/mL at 37∘C with 5% CO
2
. Virus stocks
were prepared and titered in MARC-145 cells and stored in
aliquots at −80∘C until use. For virus infection and titration,
MEM supplemented with 2% FBS was used. PRRS modified
live virus vaccine (Ingelvac PRRS MLV) was purchased from
Boehringer Ingelheim Vetmedica Inc. PRRSV strains VR-
2332, KS-06-72109 (KS-06), and NVSL97-7895 have been
described previously [11, 12].
2.2. Pigs, Vaccination, and Challenge. Twenty conventional
large White-Duroc crossbred weaned specific pathogen-free
piglets (3 weeks of age) were divided into four groups
within the Large Animal Research Center (LARC) facility,
Kansas State University. These piglets were confirmed sera-
negative for antibodies to PRRSV by ELISA and PRPSV-
free in the blood by RT-PCR. Pigs were allowed to acclimate
for an additional week before initiation of the experiment.
The first two groups were immunized intramuscularly on
day postvaccination (DPV) 0 with vaccine (PRRS-MLV,
1 × 106 TCID
50
/pig). The other two groups were used as
control groups before challenge and remained unvaccinated
(Figure 1(a)). After four weeks the pigs were challenged with
2 × 105 TCID
50
/pig of VR-2332 or KS-06 PRRSV. Necropsy
was performed at 14 days postchallenge (DPC). Pigs were
monitored for rectal temperature for the first 9 days after
challenge and body weight once a week for the duration of
this experiment.
2.3. Collection of Blood Samples for Analysis. Blood was
collected on DPV 0, 7, 14, 21, and 28 and DPC 7 and
14. Serum was separated from clotted blood and preserved
at −20∘C. Serum was used for evaluation of viral titers,
serum neutralizing antibody titers, PRRSV-specific ELISA
antibody titers (Herdchek Porcine Reproductive and Res-
piratory Syndrome Antibody test Kit, IDEXX Laborato-
ries), and cytokine expression as described previously [12].
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized blood samples by Ficoll-Hypaque gradient
centrifugation using Histopaque-1077 (Sigma-Aldrich, St.
Louis, MO). PBMCs were used for ELISpot assay and flow
cytometry analysis as described previously [12].
2.4. Gross Lung Lesion Analysis. Pigs were humanely eutha-
nized on DPC 14 as approved by the Kansas state University
Institutional Animal Use and Biosafety Committee. The
lungs were macroscopically and microscopically evaluated
as previously described [13]. Briefly, the dorsal and ventral
surfaces of each lung lobe were given a score representing
the approximate proportion thatwas consolidated. Individual
lobe scores were used to determine an overall lung score rep-
resenting the percentage of interstitial pneumonia. Sections
of each of the 4 lobes of the right lung were fixed in 10%
buffered neutral formalin, paraffin-embedded, sectioned, and
stained with hematoxylin and eosin (H & E). Scoring of
microscopic lung pathology was done in a blinded fashion
by two veterinary pathologists in the Kansas State Veterinary
Diagnostic Laboratory. Grading was on a 4 point scale as
previously described [13].
2.5. Analysis of PRRSV Circulating in the Blood. Total RNA
was extracted from pig serum and one-step SyBR Green
real-time PCR (Bio-Rad) was performed to evaluate the
PRRSV ORF7 expression level as previously described [14].
For quantification, total RNA of a known TCID
50
of virus
was 10-fold serially diluted and was used to generate a
standard curve. The virus quantities of unknown samples
were determined by linear extrapolation of the Ct value
plotted against the standard curve.
2.6. Virus Neutralizing Antibody Titer. Virus neutralizing
antibody titers were assayed as previously described [12,
14]. Briefly, serum samples were heat inactivated (56∘C,
30min) and serially diluted before the titration. The serial
dilutions of serum samples were mixed with equal volume of
PRRSV strains: VR-2332, KS-06, or NVSL97-7895 containing
200 TCID
50
of the virus. After incubation at 37∘C for 1 h,
the mixtures were transferred to MARC-145 monolayers in
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Figure 1: Vaccination with PRRSV-MLV induced complete protection from homologous PRRSV challenge and partial protection from
heterologous challenge. (a) Experimental timeline. (b) Rectal temperature of pigs was monitored daily after PRRSV challenge. (c) Gross
lung lesion scores present in all lung lobes on DPC 14 were scored using a 4-point scale. (d) PRRSV viral RNA in the serum throughout the
study was determined by qPCR. Each bar represents the average of samples from five pigs ± SEM. ∗𝑃 < 0.05.
96-well plates and incubated for an additional 72 h at 37∘C
in a humidified atmosphere containing 5% CO
2
. Cells were
then examined for cytopathic effects (CPE). CPE was used
to determine the end-point titers that were calculated as the
reciprocal of the highest serumdilution required to neutralize
200 TCID
50
of PRRSV in 90% of the wells.
2.7. ELISpot Assay. Half million PBMCs were plated in
enriched RPMI in a 96-well multiscreen plate (Millipore,
Billerica, MA) precoated overnight with capture IFN-𝛾mAB
(BD Pharmingen, San Diego, CA). PBMCs were restimu-
lated with three different strains of PRRSV (VR-2332, KS-
06, or NVSL97-7895) at 0.1 MOI for 24 h at 37∘C. IFN-𝛾-
secreting cells were detected by biotinylated anti-pig IFN-
𝛾 detection antibody and visualized using the immunospot
image analyzer (Cellular Technology, Cleveland, OH). We
calculated the number of PRRSV-specific IFN-𝛾-secreting
cells by subtracting the number of spots in unstimulated
cultures (all samples were <10) from the count of PRRSV-
stimulated cultures. Data were presented as the mean
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numbers of antigen-specific IFN-𝛾-secreting cells per 106
PBMCs from duplicate wells of each sample.
2.8. Flow Cytometry Analysis. Flow cytometry analysis was
performed to determine different lymphocyte populations
based on the cell surface marker phenotype: T-helper
cells (CD3+CD4+CD8−), cytotoxic T lymphocytes (CD3+
CD4−CD8+), Th/memory cells (CD3+CD4+CD8+), and 𝛾𝛿
T cells (CD8+TcR1N4+). Mouse anti-pig TcR1N4 antibody
was purchased from VMRD (Pullman, WA), and the rest
of the antibodies used in this study were purchased from
BD Biosciences. Immunostained cells were acquired using a
FACS Caliber (BD Biosciences) flow cytometer as described
previously [12, 14]. Briefly, PBMC was treated with 2% pig
serum to block Fc receptors. Cells were then stained with
an appropriate Ab which was either directly conjugated to
a specific fluorochrome or with a purified Ab to pig specific
immune cell surface marker (TcR1N4). For cells stained with
a purified Ab, labeled cells were treated with antispecies
isotype specific secondary Ab conjugated with fluorochrome.
Finally, cells were fixed with 1% paraformaldehyde before
reading on a flow cytometer. Percentages of each lymphocyte
population were analyzed by 100,000 unique events using
FlowJo software (Tree Star, Inc., OR, USA).
2.9. Analysis of Cytokine Responses. Pig sera were collected at
DPC 7 to evaluate IL-4, IL-8, IL-10, IFN-𝛾, TNF-𝛼 (Life Tech-
nologies, Carlsbad, CA), and IFN-𝛼 (Abcam, Cambridge,
MA) secretion profiles by ELISA. Procedures were performed
as per themanufacturer’s instructions. For a given sample, the
OD
450
was then transformed to concentration by applying a
linear regression formula calculated from the results of the
standards provided in each kit.
2.10. Statistical Analysis. All data were expressed as the mean
value of five pigs ± SEM. The differences in the level of
body temperature, lung pathology score, humoral response,
cytokine production, and viremia among each group were
determined by the one-way analysis of variance (ANOVA)
followed by post-hoc Tukey’s test using SigmaPlot 11 software
(Systat Software Inc., San Jose, CA). The difference in the
percentage of different T cell subpopulations was determined
by the paired 𝑡-test using SigmaPlot 11 software.
3. Results
3.1. Vaccination with PRRSV-MLV Induced Complete Protec-
tion from Homologous PRRSV Challenge and Partial Protec-
tion from Heterologous Challenge. To compare host immune
responses to challenge by different PRRSV isolates, pigs
were either vaccinated with PRRSV-MLV or a mock vaccine
(PBS) on day 0 and then challenged with homologous VR-
2332 or heterologous KS-06 PRRSV on day 28 (Figure 1(a)).
Clinically, the mean body temperature of unvaccinated pigs
challenged with the KS-06 strain of PRRSV was higher com-
pared to that in the other three groups at DPC 4 (Figure 1(b)).
The body weight of all pigs was tracked throughout
the study and weights of all groups were similar during
the vaccination phase. Interestingly, pigs vaccinated with
MLV and challenged with VR-2332 had a slightly higher
weight gain than that of the other groups onDPC 14 (data not
shown). Unvaccinated pigs that were challenged with either
VR-2332 or the KS-06 strain had higher lung lesion scores on
DPC 14 compared to those in vaccinated pigs (Figure 1(c)).
Vaccinated pigs challenged with VR-2332 showed full protec-
tion against PRRSV with average lung scores being normal
and no lung damage observed during pathological analysis.
Additionally, vaccinated pigs challenged with the KS-06
strain had moderate protection as shown by decreased lung
scores compared to that in unvaccinated-KS-06 challenged
pigs (Figure 1(c)).
In addition, complete protection in vaccinated pigs
against homologous challenge was confirmed with the
absence of PRRS viral RNA in the serum onDPC 7. As shown
in Figure 1(d), pigs vaccinated with MLV had efficiently
cleared the VR-2332 challenge virus from the blood to
undetectable levels. Vaccinated pigs challenged with the KS-
06 strain had less circulating PRRSV in the blood than that in
unvaccinated-KS-06 challenged pigs, but the difference was
not statistically significant. By DPC 14, the levels of PRRSV
virus circulating in the blood were reduced significantly in all
vaccinated groups.Therefore, our results suggest that PRRSV-
MLV can protect pigs from homologous challenge and
provide moderate protection against heterologous PRRSV
challenge.
3.2. Serum Neutralizing Antibody Titer Is Associated with
PRRSV Vaccination-Induced Protection against Homologous
and Heterologous Challenge. It has been shown that a vigor-
ous anti-PRRSV antibody response in pigs is seen early after
vaccination or PRRSV exposure [15]. To determine antibody
responses, we analyzed PRRSV-specific ELISA antibodies in
homologous- and heterologous-challenged pigs using com-
mercial IDEXX ELISA kit. Serum samples were collected
at various time points and used to determine the PRRSV-
specific antibody levels. As shown in Figure 2(a), vaccinated
pigs produced PRRSV-specific antibodies starting fromDPV
14. Interestingly, the antibody titers in vaccinated pigs were
not further enhanced by PRRSV challenge. Additionally, it
was found that unvaccinated pigs challenged with the KS-
06 isolate showed a faster onset and higher ELISA anti-
body titers than unvaccinated pigs challenged with VR-2332
(Figure 2(a)).
However, there is no evidence that early anti-PRRSV
antibody response plays a role in the protection against
PRRSV infection. In contrast, later appearing antibodies
with PRRSV neutralizing activity have been shown to play
a critical role in anti-PRRS immunity. A previous study
showed that passive transfer of neutralizing antibodies with a
titer of 8 to recipient piglets protected them from challenge-
induced viremia, while transfer of serum titers of 32 pro-
duced sterilizing immunity [15], suggesting that neutralizing
antibody titers over 8 can protect pigs from PRRSV. The
ability of a vaccine (modified live or inactivated) to induce
PRRSV neutralizing antibodies to specific PRRSV isolates
influences the level of protection the vaccinated pig has to
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Figure 2: Serum neutralizing antibody titer is associated with PRRSV vaccination-induced protection against homologous and heterologous
challenge. (a) PRRSV-specific antibodies were detected in the serum using IDEXX ELISA kit. The threshold for positive sera was set at a
sample to positive (𝑠/𝑝) ratio of 0.4 according to the manufacturer’s instructions. ((b)–(d)) Serum samples were titrated on MARC-145 cells
and the levels of anti-PRRSV neutralizing Abs were determined as the reciprocal of the highest dilution that could inhibit CPE. Data were
shown as mean ± SEM for 5 pigs per group. ∗𝑃 < 0.05.
the specific challenge strain [15, 16]. Therefore, we analyzed
the PRRS virus neutralizing antibody (VN) titers in the serum
of different treatment groups. As shown in Figure 2(b), MLV
vaccinated pigs began to develop VN titers to VR-2332 at
DPV 28 and the titers were significantly higher at the end
of the study as compared to those in unvaccinated pigs. It
is worth noting that high titer of VN antibodies against the
KS-06 stain was detected only in pigs vaccinated with MLV
but not in unvaccinated pigs after both groups of pigs were
challenged with the KS-06 strain (Figure 2(c)). To assay for
broad neutralizing activity, another PRRSV strain, NVSL97-
7895, was used to measure the VN titer of all serum samples.
As shown in Figure 2(d), VN antibodies against NVSL97-
7895 were developed only in vaccinated pigs, and the serum
VN titers in vaccinated pigs challenged with the KS-06 strain
were higher than those in vaccinated pigs challenged with
the homologous VR-2332. This indicates that pigs receiving
vaccination followed by challenge with a different strain of
PRRSV may generate antibodies with a broader neutralizing
spectrum.
3.3. PRRSV-Dependent Cytokine Expression Patterns Are
PRRSV Challenge Strain Specific. Compared to MLV vacci-
nated pigs challenged with the KS-06 strain, unvaccinated
pigs displayed significantly higher IFN-𝛼 level in the serum
(Figure 3(a)). In contrast, the difference in IFN-𝛼 produc-
tion was not detected between vaccinated and unvaccinated
pigs after they were challenged with VR-2332. Interestingly,
vaccinated pigs produced significant higher levels of IL-8
compared to unvaccinated pigs after they were challenged
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Figure 3: PRRSV-dependent cytokine expression patterns are PRRSVchallenge strain specific. (a) Innate and (b) adaptive cytokine expression
profiles in the sera of pigs at DPC 7were tested by ELISA. (c) PBMCs collected at DPC 14 were restimulated with VR-2332, KS-06, or NVSL97-
7895 strains of PRRSV. IFN-𝛾-secreting cells were then analyzed by ELISpot assay. Data were shown as mean ± SEM for 5 pigs per group.
∗
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with VR-2332 (Figure 3(a)). TNF-𝛼 expression levels were
low in all pigs and there was no significant difference among
treatment groups. Furthermore, serum IL-10 levels were
significantly higher in unvaccinated pigs after KS-06 PRRSV
challenge than those in vaccinated pigs (Figure 3(b)). In
contrast, vaccinated pigs displayed a higher level of serum
IL-4 after VR-2332 challenge compared to unvaccinated pigs
(Figure 3(b)). There was no significant difference in serum
levels of IFN-𝛾 among all treatment groups.
Vaccination with PRRS-MLV has been shown to induce
the production of IFN-𝛾-secreting cells as a mechanism of
protecting pigs against PRRSV viremia [17]. Therefore, the
frequency of IFN-𝛾-secreting cells in PBMCs was evaluated
on DPC 14 in a recall response in which PBMCs were
restimulated with VR-2332, KS-06, or NVSL97-7895 PRRSV.
As shown in Figure 3(c), when restimulated with VR-2332,
PBMCs from vaccinated pigs challenged with the KS-06
strain developed more IFN-𝛾-secreting cells than those from
the other three groups. When restimulated with KS-06 or
NVSL97-7895, PBMCs fromKS-06 challenged pigs produced
significantly higher amount of IFN-𝛾-secreting cells than that
from pigs challengedwith VR-2332. Finally, the ratios of IFN-
𝛾-secreting cells in PBMCs restimulated with KS-06 PRRSV
in all treatment groups were significantly lower than those in
PBMCs restimulated with VR-2332 or NVSL97-7895.
3.4. T Lymphocyte Subpopulations Vary betweenUnvaccinated
and Vaccinated Groups and Are Independent of PRRSV Chal-
lenge Strain. T lymphocyte subpopulations are reported to
vary in pigs after challenge with different PRRSV strains [18].
In this study, we evaluated the changes in frequency of various
lymphocyte populations before and after PRRSV challenge
in all experimental groups. On DPV 28, the frequencies of
T-helper cells (Figure 4(a)), cytotoxic T lymphocytes (CTLs;
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Figure 4: T lymphocyte subpopulations vary between unvaccinated and vaccinated groups and are independent of PRRSV challenge
strain. PBMCs were isolated from pigs at necropsy (DPC 14) and T cell subsets were determined by flow cytometry analysis according
to their phenotypes. Shown are the percentages of (a) T-helper cells that were CD3+/CD4+/CD8−, (b) Cytotoxic T lymphocytes that were
CD+CD4−CD8+, (c) Th/memory cells that were CD3+CD4+CD8+, and (d) 𝛾𝛿 T cells that were CD8+TcR1N4+. Data were shown as mean ±
SEM for 5 pigs per group. ∗𝑃 < 0.05.
Figure 4(b)), and 𝛾𝛿 T cells (Figure 4(d)) in PBMCs were
similar in vaccinated and unvaccinated pigs, while the fre-
quencies ofTh/memory cells in unvaccinated pigs were lower
compared to those in vaccinated pigs (Figure 4(c)). On DPC
14, the frequencies of T-helper, Th/memory, and 𝛾𝛿 T cells
in PBMCs from vaccinated pigs were higher than those from
unvaccinated pigs. It is worth noting that the frequencies
of various T cell populations in PBMCs from vaccinated
or unvaccinated pigs were not affected by the difference in
challenge strains (VR-2332 versus KS-06), suggesting that
PRRSV challenge strain does not affect T cell subpopulations.
4. Discussion
As one of the most prevalent diseases in swine, PRRS has
caused vast economic losses to the pig industry worldwide.
Adding to its devastation, the rapid evolution rate of PRRS
virus generates countless genetically distinct field isolates,
many of which have increased pathogenic ability [2, 10, 18].
Recent outbreaks of PRRSV in China were characterized by
highmorbidity/mortality and commercially available PRRSV
vaccines offered no protection [19, 20]. This demonstrates
that current commercial vaccines offer limited or no pro-
tection from newly emerging PPRSV field strains. Therefore,
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studies on the difference of immune responses to homologous
and heterologous challenge lay an important foundation for
the development of effective vaccines and eradiation strate-
gies. The present study evaluated the differences of immune
responses between vaccinated and unvaccinated pigs when
challenged with homologous or heterologous PRRSV. Here
we demonstrate that serum neutralizing antibody titers
are associated with PRRSV vaccination-induced protection
against homologous and heterologous challenge.
A recent review suggests that antibodies directed against
both nonstructural and structural proteins including NSP2,
GP2, GP4, and GP5 may possess PRRSV neutralizing activ-
ity [5], and the variability within GP5 may explain the
deficiency in cross-protection of current vaccines against
heterologous strains of PRRSV. VR-2332 (homologous) and
KS-06 strain (heterologous), the PRRS viruses used for
challenge experiments in this study, share 99.7% or 90.2%
similarity with the PRRSV-MLV vaccine strain based on GP5
amino acid sequence, respectively. Fromgross lung pathology
and viremia results, homologous VR-2332 PRRSV infection
was fully prevented after vaccination with PRRSV-MLV as
evidenced by lack of virus in sera on DPC 7 and normal
gross lung pathology scores (Figures 1(c) and 1(d)). Gross
lung pathology scores in the vaccinated pigs challenged with
the KS-06 strain were decreased compared to those in the
unvaccinated pigs, which indicate MLV vaccination can lead
to partial protection from heterologous PRRSV.These results
allow us to compare the immune responses from pigs with
complete, partial, and no (unvaccinated) protection against
PRRSV challenge.
By DPV 14, antibodies specific for N proteins of PRRSV,
as measured by the IDEXX ELISA kit, were detected in
vaccinated pigs and increased throughout the experimental
period. PRRSV-specific antibodies were similar between
vaccinated groups throughout the study, suggesting that anti-
N protein antibodies are not predictive of PRRSV protection.
Interestingly, we did observe that KS-06 PRRSV challenge
induced a faster anti-PRRSV antibody response as compared
to the vaccine strain, suggesting that more virulent strains
could induce a stronger antibody response.
In contrast to anti-N protein antibodies, virus neutral-
izing antibodies (VNs) have been shown to correlate with
protection from PRRSV [15, 16, 21]. We found that VNs to
different PRRSV strains did not start to emerge until DPV
28 in the vaccinated pigs. At the time of PRRSV challenge
(DPV 28), vaccinated pigs developed higher VN titers to
VR-2332 (Figure 2(b)) than to KS-06 strain (Figure 2(c)),
suggesting an association between PRRSV strain-specific VN
titer and level of protection from PRRSV. Vaccinated pigs did
not develop VNs to KS-06 after vaccination but developed
significantly higher VN titers to KS-06 as compared to
the other three groups two weeks after challenge, which
suggests that the KS-06 specific VN could be induced by
KS-06 challenge (Figure 2(c)). Also, vaccinated and KS-06
challenged pigs developed a higher level of VN antibodies to
the heterologous NVSL97-7895 PRRSV strain (Figure 2(d)).
This result supports the notion that two vaccinations with
different PRRSV strains can generate higher neutralizing Abs
and broader cross-protection against various PRRSV field
strains. Similar observation has been reported in influenza
virus vaccination strategy studies [22].
It was reported that PRRSV can inhibit the expression
of IFN-𝛼 [23]. However, we found that the level of IFN-
𝛼 was increased in unvaccinated pigs challenged with KS-
06 virus. Similar to previous reports, serum level of IFN-
𝛼 is not associated with the PRRS virus clearance in pigs
after viral challenges [18]. The serum level of inflammatory
cytokine IL-8 in vaccinated pigs challenged with homologous
VR-2332 virus was the highest among all treatment groups
(Figure 3(a)). Our results are consistent with previous studies
which have shown that low level of serum IL-8 is seen in
persistent PRRSV infection, and elevated IL-8 levels in serum
are correlatedwith the clearance of PRRS virus [24].However,
it remains to be determined how elevated IL-8may contribute
to the clearance of PRRS virus in vaccinated pigs andwhether
the level of serum IL-8 can be used to predict vaccination-
induced protection in pigs.
The expression of IL-4 was significantly higher in vac-
cinated pigs as compared to that in unvaccinated pigs after
KS-06 challenge.This and our previous study [12] and results
from others [25] suggest that increased IL-4 expression may
play a positive role in vaccination-mediated clearance of het-
erologous PRRS virus. However, IL-4 level in the serum may
not have a direct role in protecting pigs fromPRRSV infection
since pigs challenged with homologous PRRSV (VR-2332)
did not show increased IL-4 production. Thus, whether or
not IL-4 plays an important role in the development of
vaccination-induced protection against PRRSV has yet to be
explored in future studies.
PRRSV infection has been shown to induce a strong
immunosuppressive response characterized by promoting
the secretion of IL-10 to antagonize the protective Th1
immune response [26]. In our study, we found that IL-10
production in the serum was increased in unvaccinated pigs,
but not in vaccinated pigs, when they were challenged with
theKS-06 strain (Figure 3(b)). In contrast, both unvaccinated
and vaccinated pigs challenged with VR-2332 had similar
levels of serum IL-10. The level of serum IL-10 in PRRS
infection has been reported to be virus strain-dependent,
which may be related to the virulence of each viral isolate
[26]. Thus, the difference in IL-10 production between the
two challenged groups may be due to the fact that the KS-06
isolate is more virulent than the VR-2332 isolate.
IFN-𝛾 is a key cytokine that is associated with host cell-
mediated immunity (CMI) response, which is secreted by
natural killer cells and several different T cell subpopulations.
A report byXiao et al. shows that the level of IFN-𝛾 expression
after PRRSV infection was variable and did not correlate
with virus load [27]. Similar to their findings, we did not
observe any changes to serum levels of IFN-𝛾 among the four
treatment groups (Figure 3(b)). In a recall response, IFN-𝛾-
secreting cells from memory lymphocytes were calculated
by stimulating PBMCs with different PRRSV isolates. MLV
vaccination generated higher frequency of IFN-𝛾-secreting
cells. However, PBMCs isolated from vaccinated and KS-06
challenged pigs generated more IFN-𝛾-secreting cells when
restimulated with homologous or heterologous PRRSV as
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compared to those from unvaccinated pigs (Figure 3(c)).
We found that the lowest number of IFN-𝛾-secreting cells
was from PBMCs restimulated with the KS-06 strain, as
compared to another heterologous strain NVSL97-7895 or
VR-2332 stimulation. This may be due to the fact that the
KS-06 isolate is more virulent than the other two strains and
can cause a stronger immunosuppression during infection
[18]. Our results suggest that increased IFN-𝛾 expression does
not correlate with protection against PRRSV as evidenced
by lower levels of IFN-𝛾 in fully protected vaccinated pigs
challenged with VR-2332 compared to partially protected
vaccinated pigs challenged with KS-06 strain. Therefore, the
role of IFN-𝛾 in the protection from PRRSV infection needs
to be further explored.
A high frequency of 𝛾𝛿 T cells in pigs is considered to be
related to the activation status of the innate immune system,
and CD4+CD8+ double positive T cells possess memory, T-
helper, and cytolytic properties [28, 29]. Although significant
increases in the frequency of T-helper, Th/memory, and 𝛾𝛿 T
cells in PBMCswere observed in vaccinated pigs compared to
that in unvaccinated pigs, and this may suggest a protective
role of these cells against PRRSV infection, this parameter
cannot predict the level of protection since changes in T
cell subpopulations are similar between fully and partially
protected groups of pigs.
5. Conclusion
Difference of immune responses between vaccinated and
unvaccinated pigs challenged with either homologous or
heterologous PRRSV has been presented in this study. A
better understanding of immune response profiles leading
to full and partial protection from PRRSV challenge will
facilitate the development of more efficacious vaccines for a
broader cross-protection as well as new strategies combating
various circulating PRRS virus strains.
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